Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Shares Jump 8.8 Percent on Positive Research News

NEW YORK, Dec. 2 (GenomeWeb News) - Shares in Sequenom were up 8.8 percent at $.99 in mid-afternoon trading today after the company said that a major US university has used its genotyping technology to identify SNPs in E. coli.

The increase in share price, which was accompanied by heavy trading volume, represents the third straight day of gains for the San Diego-based high-throughput genotyping company. The stock has slid from a high of $4.50 in late January to around a dollar, where it has hovered since around mid-October.


If the stock closes below $1 today, it will mark 29 consecutive trading days that the shares have traded below the Nasdaq's minimum benchmark. Failing to trade for that minimum for 30 consecutive trading days would trigger a warning letter from the exchange, which could lead to Sequenom being delisted from the Nasdaq Nationl Market demoted to the Nasdaq SmallCap market.


Sequenom in September escaped receiving such a letter from the Nasdaq by a similar one-day margin.

The shares began their current climb in overnight trading yesterday after Sequenom said that the Universityof Californiaat San Diegohad used its flagship MassArray technology to conduct automated, high-throughput mutation-detection studies on E. coli.

The research, led by Bernhard Palsson, professor of bioengineering at UCSD, is published in the December issue of Genome Research.

Charles Cantor, Sequenom CSO, said that the research represents the first time that the company's MassArray platform has been used to conduct high throughput genetic analysis of bacteria, and provides a foundation for the development of large scale comparative sequencing processes using the technology.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.